Summary
Vertex Pharmaceuticals reported its second-quarter 2011 financial results, marked by the significant event of beginning to market its hepatitis C drug, INCIVEK (telaprevir), in the United States. This led to the generation of $74.5 million in product revenue during the quarter. While the company continues to invest heavily in research and development, particularly for its cystic fibrosis program with VX-770 nearing regulatory submission, the INCIVEK launch represents a pivotal moment for revenue generation and future profitability. The company's financial performance in the quarter showed a reduced net loss attributable to Vertex compared to the prior year, largely driven by the new product revenue and a decrease in non-operating expenses. However, operating costs and expenses increased substantially due to commercialization efforts for INCIVEK and ongoing R&D investments. Vertex also entered into a significant collaboration agreement with Alios BioPharma in June 2011, consolidating Alios' financials and adding substantial intangible assets and goodwill to its balance sheet, highlighting Vertex's strategy of expanding its pipeline through acquisitions and collaborations.
Financial Highlights
50 data points| Revenue | $114.42M |
| Cost of Revenue | $5.40M |
| Gross Profit | $109.02M |
| R&D Expenses | $173.60M |
| SG&A Expenses | $96.66M |
| Operating Expenses | $280.31M |
| Operating Income | -$165.89M |
| Interest Expense | $6.96M |
| Net Income | -$174.07M |
| EPS (Basic) | $-0.85 |
| EPS (Diluted) | $-0.85 |
| Shares Outstanding (Basic) | 204.41M |
| Shares Outstanding (Diluted) | 204.41M |
Key Highlights
- 1Vertex Pharmaceuticals began generating significant product revenue in Q2 2011 with the launch of INCIVEK (telaprevir) in the United States, recording $74.5 million in net product revenues.
- 2The company reported a net loss attributable to Vertex of $174.1 million for Q2 2011, an improvement from the $200.0 million loss in Q2 2010, driven by increased revenues and reduced non-operating expenses.
- 3Research and Development (R&D) expenses increased by 12% to $173.6 million for the quarter, reflecting continued investment in drug candidates like VX-770 for cystic fibrosis, which is nearing regulatory submission.
- 4Sales, General, and Administrative (SG&A) expenses saw a substantial increase of 136% to $96.7 million, primarily due to the expansion of the commercial organization and marketing costs associated with the INCIVEK launch.
- 5In June 2011, Vertex entered into a significant license and collaboration agreement with Alios BioPharma, including a $60 million upfront payment and consolidating Alios' financials due to its VIE status. This resulted in the addition of $250.6 million in intangible assets (in-process R&D) and $7.4 million in goodwill.
- 6The company's cash, cash equivalents, and marketable securities decreased to $593.5 million as of June 30, 2011, down from $1.0 billion at the end of 2010, due to operating expenditures, the Alios upfront payment, and capital expenditures, partially offset by stock issuances.
- 7Vertex expects its current cash position, along with expected cash flows from INCIVEK sales and potential future royalty and milestone payments, to be sufficient to fund operations for at least the next twelve months.